Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419343 | 0.85 | CYP2C19 (0.32) | CYP2C19FFAR3 | |
| SCHEMBL873448 | 0.85 | CYP2C19 (0.32) | CYP2C19FFAR3 | |
| SCHEMBL11741871 | 0.83 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL11741874 | 0.83 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL11741880 | 0.83 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL9470268 | 0.81 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL13735212 | 0.78 | CETP (0.35) | — | |
| SCHEMBL17840952 | 0.76 | — | — | |
| SCHEMBL30716833 | 0.76 | CYP2C19 (0.42) | CYP2C19FFAR3 | |
| SCHEMBL245571 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4410773-A2 | PROCESS FOR THE SYNTHESIS OF (S) 3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2024-08-07 | — | — | EP | claimed |
| EP-3784649-A1 | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2021-03-03 | — | — | EP | claimed |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | NORTHWESTERN UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4410773-A2 | PROCESS FOR THE SYNTHESIS OF (S) 3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | Northwestern University (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3784649-B1 | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | UNIV NORTHWESTERN (US) | 2024-07-31 | — | — | EP | disclosed |
| JP-2024096834-A | PROCESS FOR SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | ノースウェスタン ユニバーシティ | 2024-07-17 | — | — | JP | disclosed |
| CN-111471021-B | Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-9701643-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9139534-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2699553-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
| WO-2007072506-A2 | POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND PROCESSES THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072507-A2 | POLYMORPHIC FORMS OF DOLASETRON BASE AND PROCESSES OF PREPARING DOLASETRON BASE, ITS POLYMORPHIC FORMS AND SALT THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | CYP2C19 4834/4885FFAR3 2945/4885 |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | CYP2C19 4834/4885FFAR3 2945/4885 |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | CYP4A11, CYP3A43, VKORC1 | CYP2C19 39/4885FFAR3 3911/4885 |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | CYP2C19 4834/4885FFAR3 2945/4885 |
| US-12331006-B2 | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | SULT1E1, QPCT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP2C19 70/4885FFAR3 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.